Innovation in Ophthalmology Pushes Forward

Innovation in Ophthalmology Pushes Forward
SAN FRANCISCO — The future of innovation in ophthalmology is promising, with more forward movement than drag, according to a speaker here.

“The tailwinds are stronger than the headwinds,”

William J. Link, PhD, managing director of Versant Ventures, told colleagues interested in supporting innovation in the ophthalmic space at the Ophthalmology Innovation Summit.

Key criteria needed to push innovation forward include a large and accessible market, a significant unmet or underserved need, and disruptive technology that can be refined. These criteria are being met in the ophthalmology market, he said.

Other influential factors include working with a resilient and tenacious team and knowing the regulatory pathway, he said.

“The predictability of the regulatory pathway is very influential in innovation,”

Link said, citing the length of the process as one of the factors that can hold back innovation.

The drivers of innovation oftentimes are the physicians themselves, according to Link.

“They’re closest to the need; they’re closest to the patient,” he said.

Innovation is rewarded when the end result is safe and effective for patients, in addition to being good for the customer, he said.

Disclosure: Link is managing director of Versant Ventures.

Article was originally posted on Healio.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

Novartis-Regeneron Dispute Enters a New Phase

Novartis-Regeneron Dispute Enters a New Phase

The Myopia Management Market How Big is Big Web

The Myopia Management Market: ‘How Big is Big?’

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System (1)

Despite Interruption, Pixium Vision Aims to Keep Moving Toward Commercializing Prima System

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

Gyroscope Therapeutics Completes Financing to Advance Gene Therapy Candidate for GA

Article Graphic for Anterior Clinical Panel Web

Anterior Segment Advances That ‘Won’ 2020 and Those Poised To Disrupt the Future

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol Web

With $36 Million, Visus Starts Phase II Trial of Presbyopia Drop Brimochol

About The Author

Tom Salemi

Tom serves as Content Director for Healthegy, joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products. At Healthegy, Tom hosts the OIS Podcast and MedtechTalk, contributes to the Engage and Eye on Innovation newsletters and assists in the agenda development of new and existing conferences.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

PODCASTS